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ABSTRACT
Objective:  To assess the outcome of the treatment of primary vaginal cancer using definitive 
radiotherapy (RT) and to evaluate the prognostic factors of survival.
Methods:  The medical records of nine institutions were retrospectively reviewed to find the 
patients with vaginal cancer treated with definitive RT with or without chemotherapy. A total 
of 138 patients met the inclusion criteria. None had undergone curative excision.
Results:  The median follow-up time of the survivors was 77.6 months and the median 
survival time was 46.9 months. The 5-year overall survival, cancer-specific survival (CSS), and 
progression-free survival (PFS) rates were 68%, 80%, and 68.7%, respectively. In the survival 
analysis, the multivariate analysis showed that a lower the International Federation of Gynecology 
and Obstetrics (FIGO) stage and prior hysterectomy were favorable prognostic factors of CSS, 
and a lower FIGO stage and diagnosed prior to year 2000 were favorable prognostic factors of 
PFS. In the subgroup analysis of the patients with available human papillomavirus (HPV) results 
(n=27), no statistically significant relationship between the HPV status and recurrence or survival 
was found. Grade 3 or 4 acute and late toxicity were present in 16 and 9 patients, respectively. 
The FIGO stage and the tumor size were predictors of severe late toxicity.
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Conclusion:  The data clearly showed that a higher FIGO stage was correlated with a 
worse survival outcome and higher severe late toxicity. Therefore, precise RT and careful 
observation are crucial in advanced vaginal cancer. In this study, the HPV status was not 
related to the survival outcome, but its further investigation is needed.
Keywords: Radiotherapy; Stage; Vaginal Neoplasms
INTRODUCTION
Primary vaginal cancer is a rare malignancy, accounting for 1% to 2% of all gynecologic 
malignancies. According to the annual report on cancer statistics in South Korea in 2012, the 
annual incidence of vaginal cancer accounts for 0.1% of the all-cancer registry, with a 5-year 
incidence of approximately 240 patients, which is lower than the reported data [1]. Therefore, 
most studies of primary vaginal cancer are small due to the rarity of the disease.
To treat vaginal cancer, surgical options can be considered for highly selected small and 
localized early-stage patients. Radiotherapy (RT) with or without chemotherapy is a treatment 
of choice for most primary vaginal cancer patients. Additional chemotherapy is often used 
by extrapolating cervical cancer data, yet no randomized trial has compared RT alone and 
concurrent chemoradiotherapy (CCRT). Recently, the National Cancer Data Base of the 
United States has reported the results of the study of the largest population of primary vaginal 
cancer patients and provided survival data and prognostic factors of data for over 8,000 
patients, which revealed the superiority of CCRT over RT alone in the treatment of primary 
vaginal cancer [2]. However, detailed data were significantly missing, such as the purpose of 
chemotherapy or RT (inductive or definitive) and the toxicity profile. Moreover, though this 
study was designed to deal with definitive RT, patients who had undergone lymphadenectomy 
were included.
To overcome the limitations of previous studies of primary vaginal cancer due to the rarity of 
the disease, the Korean Radiation Oncology Group (KROG) performed a multi-institutional 
retrospective study, the results of which are reported herein.
MATERIALS AND METHODS
1. Patients and tumor characteristics
This multicenter retrospective study was conducted on primary vaginal cancer patients treated 
with definitive RT with or without chemotherapy from June 1976 to November 2011 in nine 
institutions approved by KROG (KROG, 12-09). Patients with distant metastasis were excluded, 
except patients who had para-aortic lymph node metastasis, as those could be covered by the 
extended pelvic RT field. Patients with a history of curative excision, who were in the Tis stage, 
or who had a histology of vaginal melanoma were also excluded. Patients were diagnosed as 
vaginal cancer in case where there was no evidence of recurrence of cervical/endometrial cancer 
for more than 10 years or when histologic subtypes were different from the two diseases. This 
study was approved by the Institutional Review Board of each of the included institutions.
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A total of 152 patients in nine institutions who satisfied the inclusion criteria were identified. 
Of these, 11 patients with incomplete RT or an RT dose ≤ 50.4 Gy to the vagina were excluded. 
Three patients whose follow-up period was less than four months were also excluded. Finally, 
138 patients were evaluated for the survival analysis. The patient, tumor, and treatment 
characteristics are shown in Table 1. The median age was 61 years (range, 30 to 84 years). Seven 
patients had a history of cervical cancer, and 13 had carcinoma in situ (CIS) before vaginal 
cancer. Fifty-five patients had undergone hysterectomy, 22 of them for malignancy (seven for 
cervical ca, one for endometrial cancer, one for malignant mixed Müllerian tumor, and 13 
Table 1.  Patient, tumor, and treatment characteristics
Characteristic No. of patients (%)
Age (yr), median (range) 61 (30–84)
Previous history of cervical cancer
   Yes 7 (5)
   No 131 (95)
Previous history of CIS
   Yes 13 (9)
   No 125 (91)
Prior hysterectomy
   Yes 55 (40)
   No 83 (60)
Histology
   SqCC 119 (86)
   Adenocarcinoma 6 (4)
   Others 13 (10)
Size (cm)
   ≤4 105 (76)
   >4 33 (24)
Year of initial diagnosis
   <2000 57 (41)
   ≥2000 81 (59)
FIGO stage
   I 59 (43)
   II 31 (22)
   III 26 (19)
   IVA 19 (14)
   IVB (with para-aortic metastasis) 3 (2)
HPV status
   Positive 17 (12)
   Negative 10 (7)
   Unknown 111 (81)
Treatment
   RT alone 81 (59)
   CCRT 46 (33)
   Neoadjuvant chemotherapy+RT or CCRT 11 (8)
RT technique
   EBRT alone 22 (16)
   Brachytherapy alone 4 (3)
   EBRT+brachytherapy 112 (81)
Total dose (Gy)
   <80 87 (63)
   ≥80 51 (37)
CCRT, chemoradiotherapy; CIS, carcinoma in situ; EBRT, external beam radiotherapy; FIGO, International 
Federation of Gynecology and Obstetrics; HPV, human papillomavirus; RT, radiotherapy; SqCC, squamous cell 
carcinoma.
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for CIS) and 33 for various benign diseases such as uterine fibroids or pelvic inflammatory 
disease. One patient had a pelvic RT history because of cervical cancer. All the patients 
underwent a thorough gynecological examination at the time of their diagnosis, with chest 
X-ray for 90% of the patients, cystoscopy for 59%, colonoscopy for 70%, a pelvic computed 
tomography (CT) scan for 54%, a pelvic magnetic resonance imaging scan for 62%, and 
a positron emission tomography-CT scan for 28%. Generally, the size was measured by 
imaging studies if available, or by gynecological exams.
Eighty-six percent of the patients were diagnosed with squamous cell carcinoma (SqCC), and 
24% had tumors larger than 4 cm. The human papillomavirus (HPV) status of the tumor was 
available in 27 patients, and 17 (63%) of those were HPV-positive. The HPV-positive tumors 
were all SqCC.
When the patients who had undergone RT alone were compared with the CCRT group 
(n=127), the RT alone group showed a stronger history of cervical cancer or CIS, and more 
patients received the treatment before the year 2000 (Table 2). Moreover, in the comparison 
of the patients treated before the year 2000 and after 2000, there were more older patients, 
more large tumors, and more CCRT procedures performed on the patients treated after 2000, 
whose total dose was also lower (Table 3).
Table 2.  Patients characteristics according to the treatment (n=127)
Characteristic RT alone (n=81) CCRT (n=46) p-value
Age (yr) 0.065
   <60 33 (41) 27 (59)
   ≥60 48 (59) 19 (41)
History of cervical cancer or CIS 0.010
   Yes 17 (21) 2 (4)
   No 64 (79) 44 (96)
Prior hysterectomy 0.852
   Yes 34 (42) 18 (39)
   No 47 (58) 28 (61)
Histology 0.056
   SqCC 74 (91) 36 (78)
   Non-SqCC 7 (9) 10 (22)
Size (cm) 0.284
   ≤4 64 (79) 32 (70)
   >4 17 (21) 14 (30)
Year of initial diagnosis <0.001
   <2000 46 (57) 4 (9)
   ≥2000 35 (43) 42 (91)
FIGO stage 0.124
   I–II 56 (69) 25 (54)
   III–IVB 25 (31) 21 (46)
RT technique 0.300
   EBRT alone 13 (16) 7 (15)
   Brachytherapy alone 4 (5) 0
   EBRT+brachytherapy 64 (79) 39 (85)
Total dose (Gy) 0.342
   <80 49 (61) 32 (70)
   ≥80 32 (39) 14 (30)
Values are presented as number (%).
CCRT, concurrent chemoradiotherapy; CIS, carcinoma in situ; EBRT, external beam radiotherapy; FIGO, 
International Federation of Gynecology and Obstetrics; RT, radiotherapy; SqCC, squamous cell carcinoma.
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2. Treatment
Eighty-one percent of the patients had undergone both external beam radiotherapy (EBRT) 
and brachytherapy; 16%, EBRT alone; and 3%, brachytherapy alone. The pelvic RT field of the 
134 patients who had undergone EBRT basically included their entire vagina and their pelvic 
lymph nodes, and 53 of them were selected to undergo extended field pelvic RT that included 
their inguinal lymph node or para-aortic lymph node regions. The median dose for the pelvis 
was 46 Gy (range, 39.6 to 54 Gy). Boost doses were given to 49 patients for gross primary 
tumor, the parametrial region, or lymph nodes. Among the node-positive patients (n=34), 27 
underwent boost irradiation of their grossly enlarged lymph nodes.
For the intracavitary brachytherapy, low-dose rate from a cesium-137 radioactive source 
(median dose, 40.2 Gy; range, 30 to 65.2 Gy) was used for 35 patients in two hospitals, and 
high-dose rate via iridium-192 (median dose, 30 Gy; range, 10 to 50 Gy), for 80 patients 
in seven hospitals. Vaginal cylinders or Fletcher-Suit-Delclos colpostats were used for 
brachytherapy. The dose prescription point was 0.5 or 1.0 cm in depth to the surface of 
the vaginal mucosa to cover the gross residual tumor after EBRT, which was made upon 
clinician's decision.
Table 3.  Patients characteristics according to the year of diagnosis
Characteristic Before 2000 (n=57) After 2000 (n=81) p-value
Age (yr) 0.010
   <60 34 (60) 31 (38)
   ≥60 23 (40) 50 (62)
History of cervical cancer or CIS 0.628
   Yes 7 (12) 13 (16)
   No 50 (88) 68 (84)
Previous history of hysterectomy 0.113
   Yes 18 (32) 37 (46)
   No 39 (68) 44 (54)
Histology 0.455
   SqCC 51 (90) 68 (84)
   Non-SqCC 6 (10) 13 (16)
Size (cm) 0.026
   ≤4 49 (86) 56 (69)
   >4 8 (14) 25 (31)
FIGO stage 0.587
   I–II 39 (68) 51 (63)
   III–IVB 18 (32) 30 (37)
Treatment <0.001
   RT alone 46 (81) 35 (43)
   CCRT 4 (7) 42 (52)
   ICT+ other Tx 7 (12) 4 (5)
RT technique 0.111
   EBRT alone 5 (9) 17 (21)
   Brachytherapy alone 1 (2) 3 (4)
   EBRT+brachytherapy 51 (89) 61 (75)
Total dose (Gy) 0.007
   <80 28 (49) 59 (73)
   ≥80 29 (51) 22 (27)
Values are presented as number (%).
CCRT, chemoradiotherapy; CIS, carcinoma in situ; EBRT, external beam radiotherapy; FIGO, International 
Federation of Gynecology and Obstetrics; ICT, induction chemotherapy; SqCC, squamous cell carcinoma; RT, 
radiotherapy; Tx, treatment.
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3. Statistical analysis
The survival durations were calculated from the first day of the initial treatment. Overall 
survival (OS) and cancer-specific survival (CSS) were defined as the time to death from any 
cause and the time to death from vaginal cancer. Loco-regional recurrence-free survival 
(LRFS) and progression-free survival (PFS) were defined as the time to the loco-regional and 
overall recurrence, respectively. The Kaplan-Meier survival graphs and statistical differences 
were presented using the log-rank test. A Cox proportional hazard model was used for the 
multivariate analysis, and the variables showed a p-value <0.2 in the log-rank test. To find 
predictors of grade 3 or 4 late toxicity, logistic regression analysis was used. All the statistical 
analyses were carried out using SPSS ver. 22 (IBM Co., Armonk, NY, USA). A p<0.05 was 
considered statistically significant.
RESULTS
1. Treatment outcome
The median follow-up time of the survivors was 77.6 months (range, 4.4 to 426.1 months). 
The median survival time was 46.9 months (range, 4.3 to 426.1 months). Twenty-seven 
patients (20%) died from vaginal cancer during the follow-up period, and 25 (18%) died from 
other causes. The 5-year OS, CSS, and PFS rates were 68%, 80%, and 68.7%, respectively. 
The 5-year LRFS rate was 74%. The 5-year OS rate in stage I of the International Federation of 
Gynecology and Obstetrics (FIGO) staging system was 75.4%; in stage II, 68.8%; in stage III, 
68%; and in stage IV, 47%. The 5-year CSS rate in stage I was 85%; in stage II, 83.6%; in stage 
III, 74.5%; and in stage IV, 69.2%. The 5-year PFS rate in stage I was 78.9%; in stage II, 66%; 
in stage III, 52.5%; and in stage IV, 65.2%.
The prognostic factors of the OS and the CSS, as well as of the 5-year survival rate, 
significantly differed. In the multivariate analysis, an age above 60 and treatment after the 
year 2000 were statistically significant for the OS. In contrast, the FIGO stage and prior 
hysterectomy were associated with the CSS (Table 4). In the same analysis, the year of the 
initial diagnosis and the FIGO stage were found to be related to the PFS, and the year of the 
initial diagnosis, to the LRFS.
Distant metastasis occurred in 19 patients (13.7%). The most common sites of the metastases 
were the lung (in five patients) and the para-aortic lymph node (in five patients), followed by 
the supraclavicular lymph node (in four patients). Two patients each had liver, cervical lymph 
node, peritoneum, and brain metastases, and one patient had bone, abdominal wall, and 
mediastinal lymph nodes.
2. Subgroup analysis of the HPV-tested patients
In the patients whose tumor HPV status was available (n=27), no statistically significant 
difference was found in all the outcomes. However, the patients with HPV-positive tumors 
all showed trends toward better survival outcomes, especially in the LRFS (5-year OS: 68.8% 
for the HPV-positive patients vs. 44.4% for the HPV-negative patients, p=0.406; 5-year CSS: 
82.4% vs. 74.1%, p=0.748; 5-year PFS: 81.6% vs. 64.8%, p=0.386; and 5-year LRFS: 93.3% 
vs. 77.8%, p=0.219).
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3. Complications
The toxicity profiles of the treated patients are listed in Table 5 and were recommended to be 
graded according to the Common Terminology Criteria for Adverse Events ver. 4.0. Sixteen 
patients (12%) had grade 3 or 4 acute toxicity; 12 (9%), grade 3 or 4 acute skin toxicity; one 
(1%), grade 3 acute gastrointestinal (GI) toxicity; and three (2%), grade 3 acute genitourinary 
toxicity. Twelve patients (8%) showed late toxicity. Grade 3 or 4 late GI toxicity occurred in 
nine patients (7%), and grade 3 or 4 genitourinary complications, in eight patients (6%). 
Grade 3 or 4 late skin toxicity developed in three patients (2%). Prognostic factors for severe 
toxicity (age, prior hysterectomy, histology, tumor size, year of initial diagnosis, FIGO stage, 
treatment, RT technique, and total dose) were evaluated by logistic regression. The result 
showed that a higher FIGO stage (I or II vs. III or IV) (odds ratio [OR], 4.153; 95% CI, 1.145 to 
15.056; p=0.03), and an over 4 cm tumor size (OR, 4.044; 95% CI, 1.189 to 13.756; p=0.025) 
were significantly related to the risk of grade 3 or 4 late toxicity.
DISCUSSION
This study presents the results of treatments of primary vaginal cancer with definitive RT in 
multiple institutions in Korea for 35 years. The presented CSS outcomes were comparable to 
or higher than those in recently reported data [3-5]. The results of this study showed that the 
prognostic factors of the OS (the age and the year of the initial diagnosis) and the CSS (prior 
hysterectomy and the FIGO stage) significantly differed. Because many deaths were unrelated 
to vaginal cancer, the CSS rather than the OS represented the survival outcome after the 
treatment of primary vaginal cancer. Therefore, the authors focused on the CSS rather than 
the OS in the interpretation of the results.
In this study, the FIGO stage was strongly associated with the CSS and the PFS in the 
multivariate analysis, as expected [3,6]. Additionally, prior hysterectomy was related to 
better CSS. It has been acknowledged that a number of vaginal neoplasms develop after 
hysterectomy [7,8]. In the recent study of Daling et al. [9], they also found that prior 
hysterectomy was a risk factor of vaginal cancer in women with no history of anogenital 
cancer. The data are consistent with the results of Chyle et al. [10] and Tran et al. [4], which 
showed the relationship between prior hysterectomy and the vaginal cancer survival outcome. 
Although the relationship was inconclusive, the researchers attributed the better survival in 
the prior hysterectomy group to early diagnosis and the smaller tumors due to the absence of 
the uterus and the lower amount of vaginal substrates.
Although the tumor size is known as an important prognostic factor of the survival of vaginal 
cancer patients, its accurate measurement is difficult without surgery due to the anatomical 
difficulties [11]. Therefore, it is difficult to apply an accurate tumor size to the prediction of 
Table 5.  Toxicity profiles in patients treated for primary vaginal cancer
Variable Acute Chronic
Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Skin 18 (13) 17 (12) 10 (7) 2 (1) 3 (2) 4 (3) 2 (1) 1 (1)
Gastrointestinal 34 (25) 22 (16) 1 (1) 0 5 (4) 10 (7) 7 (5) 2 (1)
Genitourinary 21 (15) 12 (9) 3 (2) 0 4 (3) 5 (4) 6 (4) 2 (1)
Others 7 (5) 4 (3) 0 0 1 (1) 8 (6) 0 0
Values are presented as number (%).
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the survival outcome in a clinical setting without surgical resection in the clinical setting. 
The data from the univariate analysis in this study also showed better disease control in small 
tumors (≤4 cm), as in other studies [2,3], but they were insignificant in the multivariate 
analysis in this study.
The results of this study that were difficult to interpret were that the patients treated after 
the year 2000 had much worse LRFS, PFS, and OS rates and tended to have worse CSS rates. 
Although such results remained significant after they were adjusted based on other factors in 
the multivariate analysis, increased surgery in the treatment of early-stage vaginal cancer and 
the use of neo-adjuvant chemotherapy were speculated to have facilitated curative resection 
in the previously unresectable cases. The reported results of the National Cancer Data Base 
and Surveillance, Epidemiology, and End Results data analysis after the 1990s showed 
better survival outcomes with surgery than with definitive RT, but also inherent selection 
biases [11,12]. Therefore, there could have been trends toward increased surgical resection 
before considering definitive RT in early-stage vaginal cancer. As seen in Table 3, there were 
older patients and patients with larger primary tumors in the group treated after the year 
2000. Several surgical series showed biases in the selection of surgical candidates and more 
unfavorable cases treated with RT [13-15].
Another result of this study that differed from that of other studies was that the CCRT did not 
show a survival benefit and instead, showed an inferior survival outcome in the CCRT group [2]. 
Therefore, the RT-alone group and the CCRT group were compared, as shown in Table 2, and 
the comparison revealed trends toward more non-SqCC in the CCRT group and the treatment 
of more patients after the year 2000. Therefore, selection biases were speculated in the 
decision-making on the vaginal cancer treatment modality in Korea.
Research on the effect of the tumor HPV status on vaginal cancer survival is still in its 
early stage mainly due to the rarity of vaginal cancer, but there is a presumption that the 
tumor HPV status in vaginal cancer would also contribute to the cancer development or 
the treatment response, based on the studies of head and neck cancer as well as of cervical 
cancer [16,17]. Sinno et al. [18] examined the HPV status in 60 cases of vaginal cancer, and 
found that 75% were HPV-positive and 25% were HPV-negative. The unadjusted OS rates 
in the HPV-positive patients were 57.4% and 35.7% for the HPV-negative patients, but they 
were statistically insignificant (p=0.243) [18]. This study included 27 patients with HPV test 
results, 63% of whom were HPV-positive, and their survival rates showed no statistically 
significant difference. That might have been due to the small number of patients in the 
performed studies, because the data showed a trend toward a better survival outcome in HPV-
positive patients. Therefore, a further study with a sufficient number of patients is needed.
Regarding acute toxicity, 12% of the patients experienced a severe (grade 3 or 4) acute 
complication, lower than in other studies (24% to 40%). However, the late toxicity result 
was comparable to that of other studies, in that 8% of the patients had a grade 3 or 4 late 
complication [5,10,19,20]. However, as Hegemann et al. [19] stated, clinicians grade 
toxicities differently, which makes it difficult to directly compare the results of various 
studies. However, the toxicities are still considerable. Therefore, based on these data, 
toxicities should be considered during treatment, especially late toxicities, and special 
attention should be paid to the characteristics of each tumor. The results of this study showed 
that a higher FIGO stage and a larger tumor could significantly predict severe late toxicity, as 
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mentioned in some previous studies [3,4]. Other researchers have reported the predictors 
of complications as a higher RT dose [21,22], pelvic lymphadenectomy [10], a higher FIGO 
stage, and a smoking history [3]. As mentioned, the FIGO stage is also a critical risk factor of 
the disease recurrence and worse CSS, as well as a predictor of severe late toxicity. Therefore, 
especially in the advanced stage, more precise RT such as intensity-modulated RT or 
brachytherapy planning with three-dimensional imaging should replace conventional RT to 
enhance the treatment outcome and to reduce the toxicity.
This multicenter study revealed that the institutions had heterogeneous treatment policies. 
Furthermore, the obtainable data were limited, such as the location of the tumor, tumor 
markers, detailed RT technique, and salvage treatment after recurrence, because they were 
lacking in some institutions. However, a multicenter study on this rare malignancy was 
inevitable to accrue analyzable data, because a single-institution study could not provide 
useful prognostic factors of survival due to the small number of patients, except for large 
institutions, and the study of the national database provided few of the important data. 
An attempt was made to enhance the homogeneity of the data, especially on the treatment 
schemes, by strictly excluding cases of prior excision before RT and Tis lesions, which were 
included in previous studies [2,10].
In conclusion, a survival outcome comparable to or higher than the historical data and 
moderate toxicities in the patients with primary vaginal cancer were shown, and revealed that 
a lower FIGO stage and prior hysterectomy are favorable prognostic factors. The FIGO stage 
and the tumor size were related to higher severe toxicity. Therefore, individualized precise 
treatment of advanced-stage vaginal cancer is imperative. In the patients whose tumor HPV 
status was available, 63% had an HPV-positive tumor. No relationship was found between the 
patients with HPV-positive and -negative tumors, but there was a trend toward better local 
control in the HPV-positive patients. Therefore, a further study on HPV in vaginal cancer is 
needed.
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